[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-369889-105":3,"detail-sidebar-cat-0-en-105":80,"doc-detail-369889-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":73,"head_meta":75,"extra_data":77,"updated_unix":79},105,"en","combined-anti-tumor-effects-of-metformin-and-azacitidine-in-breast-cancer-cells","Combined anti-tumor effects of metformin and azacitidine in breast cancer cells","","Breast cancer remains the most common cancer in women, and combination regimens may improve efficacy while limiting drug resistance. This study integrates bioinformatics with experimental validation to evaluate how metformin and azacitidine—an antidiabetic agent and an epigenetic regulator—affect breast cancer biology. Differential expression and network analyses identify key genes. Expression patterns are assessed across tumor and matched normal tissues, and survival associations are explored. Synergistic in vitro antitumor activity is tested in MDA-MB-231 cells with viability, migration, and qPCR assays targeting CCND1, ELAVL1, and EIF4EBP1.",{"@graph":14,"@context":72},[15,34,55],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/combined-anti-tumor-effects-of-metformin-and-azacitidine-in-breast-cancer-cells/369889/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/combined-anti-tumor-effects-of-metformin-and-azacitidine-in-breast-cancer-cells/369889.png","ImageObject",300,407,{"name":42,"@type":43},"Mary Man","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-29","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":33},"InteractionCounter",{"@type":54},"ViewAction",{"@type":56,"mainEntity":57},"FAQPage",[58,64,68],{"name":59,"@type":60,"acceptedAnswer":61},"What was the main research question of the study?","Question",{"text":62,"@type":63},"The study examined whether combining metformin and azacitidine produces synergistic anti-tumor effects in breast cancer cells and through which key genes this may occur.","Answer",{"name":65,"@type":60,"acceptedAnswer":66},"How were candidate genes and pathways identified?",{"text":67,"@type":63},"Differentially expressed genes were analyzed from the GSE45827 dataset, protein-protein interaction networks were built, key genes were detected using MCODE, and further targets were explored with Way2Drug.",{"name":69,"@type":60,"acceptedAnswer":70},"What experimental methods were used to test the drugs on breast cancer cells?",{"text":71,"@type":63},"The study assessed effects of metformin, azacitidine, and their combination on MDA-MB-231 cells using MTT viability assays, isobologram synergy analysis, wound-healing migration assays, and real-time PCR for CCND1, ELAVL1, and EIF4EBP1.","https://schema.org",{"og:url":32,"og:type":74,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":76,"canonical":32},"index,follow",{"doc_id":78,"site_id":7},369889,1791082552,{"code":4,"msg":81,"data":82},"success",[83,87,91,95,100,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":84,"show_sort_weight":85,"slug":86},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":88,"show_sort_weight":89,"slug":90},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":92,"show_sort_weight":93,"slug":94},"Exam",70,"exam",{"id":96,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},5,"Comic",60,"comic",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},6,"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":96,"slug":129},19,"General","general",{"code":4,"msg":81,"data":131},{"doc_id":78,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":33,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":108,"preview_page_count":33,"preview_urls":145},7421720224475,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Hosseini etal. BMC Cancer (2025) 25:1487 BMC Cancer  \n[https://doi.org/10.1186/s12885-025-14908-0](https://doi.org/10.1186/s12885-025-14908-0)  \nRESEARCH Open Access  \nCombined anti-tumor effects of metformin and azacitidine in breast cancer cells  \nSetayesh Sadat Hosseini 1, Nahid Askari 1* and Mohammad Mehdi Yaghoobi 1  \nAbstract  \nBackground Breast cancer is the most common cancer in women. While treatments exist, combination therapies may enhance effectiveness and reduce drug resistance. Metformin-a common diabetes medication has shown promising anticancer properties. Azacitidine, primarily an epigenetic regulator, also exhibits anticancer effects. Methods and materials The GSE45827 dataset was analyzed for differential ly expressed genes (DEGs) using GEO2Rand ShinyGO tools. Protein-protein interaction (PPI) networks were constructed with STITCH and Cytoscape, and key genes were identified using MCODE. Gene expression profiles of selected targets were compared between tumor and matched normal tissues using GTEx Portal andTNMPlot databases. Kaplan-Meier plotter was used for survival analysis, and potential drug targets were identified with Way2Drug. In vitro effects of metformin, azacitidine, and their combination on MDA-MB-231 cells were assessed using MTT assay, isobologram analysis, wound-healing assay, and real-time PCR for CCND1, ELAVL1, and EIF4EBP1 gene expression. Statistical analysis was performed.  \nResults Bioinformatics analysis identified CCND1, ELAVL1, and EIF4EBP1 as key genes in breast cancer pathogenesis. MTT assays showed that both drugs reduced cell viability in a dose-dependent manner. Isobologram analysis confirmed a strong synergistic effect from the combination. Wound-healing assays revealed significant inhibition of cancer cell migration. Real-time qPCR showed gene expression changes consistent with inhibition of cancer progression.  \nConclusion The metformin-azacitidine combination synergistically suppresses breast cancer cell proliferation, likely through coordinated modulation of CCND1, ELAVL1, and EIF4EBP1 . These findings highlight the potential of this novel drug combination in breast cancer treatment.  \nKeywords Breast cancer, Metformin, Azacitidine, Bioinformatic, Gene expression  \n*Correspondence: Nahid Askari [nahidaskari@gmail.com](nahidaskari@gmail.com)  \n1Department of Biotechnology, Institute of Science and High Technology and Environmental Sciences, Graduate University of Advanced Technology, Kerman, Iran  \n© The Author(s) 2025. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creati](http://creati)[vecommons.org/l](vecommons.org/l)icenses/by-nc-nd/4.0/.  \nIntroduction  \nBreast cancer is the most common cancer in women. Its development involves environmental, genetic, and epigenetic factors that drive tumor growth. Epigenetic changes allow cancer cells to adapt [1, 2]. Among these changes is tumor suppressor gene inactivation, which can be reactivated by specific drugs. Numerous compounds can manipulate gene modifications. These compounds enable efficient target protein ex","cbCaita7BWsFc8Dx","https://ap.wps.com/l/cbCaita7BWsFc8Dx","pdf",5011636,16,"English","# Abstract\n# Introduction\n## Background and rationale\n## In silico and experimental approaches\n## Breast cancer models and challenges\n## Drugs studied in this work","[{\"question\":\"What was the main research question of the study?\",\"answer\":\"The study examined whether combining metformin and azacitidine produces synergistic anti-tumor effects in breast cancer cells and through which key genes this may occur.\"},{\"question\":\"How were candidate genes and pathways identified?\",\"answer\":\"Differentially expressed genes were analyzed from the GSE45827 dataset, protein-protein interaction networks were built, key genes were detected using MCODE, and further targets were explored with Way2Drug.\"},{\"question\":\"What experimental methods were used to test the drugs on breast cancer cells?\",\"answer\":\"The study assessed effects of metformin, azacitidine, and their combination on MDA-MB-231 cells using MTT viability assays, isobologram synergy analysis, wound-healing migration assays, and real-time PCR for CCND1, ELAVL1, and EIF4EBP1.\"}]","Combined anti-tumor effects of metformin and azacitidine in breast cancer cells | PDF",1790185094,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1428596da43322129c37c994744809af.webp",983,1310,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/edd1ad8e6b01d5a409155951a88f26ab.webp",982,1309,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2ade80d1b2407e96e6688bb69b9b4fa8.webp",981,1308,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9cc9bf784a453155100fe8a7afe0db28.webp",980,1306]